Prelude Capital Management’s Tarsus Pharmaceuticals TARS Stock Holding History

Prelude Capital Management’s Portfolio TARS Stock Details TARS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-8,778	Closed	-$486K	–	1518
2024 Q4	$486K	Sell	8,778 -4,622	-34%	-$210K	0.03%	600
2024 Q3	$441K	Buy	+13,400	New	+$377K	0.03%	680
2024 Q2	–	Sell	-15,200	Closed	-$553K	–	1489
2024 Q1	$553K	Sell	15,200 -4,800	-24%	-$141K	0.03%	595
2023 Q4	$405K	Buy	+20,000	New	+$334K	0.03%	614
2023 Q2	–	Sell	-17,365	Closed	-$218K	–	1344
2023 Q1	$218K	Sell	17,365 -1,200	-6%	-$17.6K	0.01%	819
2022 Q4	$272K	Buy	18,565 +1,744	+10%	+$28.9K	0.01%	827
2022 Q3	$288K	Sell	16,821 -2,228	-12%	-$35.4K	0.01%	891
2022 Q2	$278K	Buy	+19,049	New	+$286K	0.01%	1107

Other funds holding TARS

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

Prelude Capital Management's TARS Position: Q1 2025 in Review

Prelude Capital Management sold out of Tarsus Pharmaceuticals (TARS) in Q1 2025, closing a stake of 8,778 shares — an estimated $486K sold.

Prelude Capital Management first reported a position in TARS in Q2 2022 and held it in 8 quarters. The position peaked at $553K in Q1 2024. 194 funds tracked by Wall St. Rank hold TARS as of Q1 2025.

Prelude Capital Management reported no remaining Tarsus Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
Prelude Capital Management sold 8,778 Tarsus Pharmaceuticals shares in Q1 2025, an estimated $486K.
Prelude Capital Management first reported a position in Tarsus Pharmaceuticals in Q2 2022 and held it in 8 quarters.
Prelude Capital Management's Tarsus Pharmaceuticals position peaked at $553K in Q1 2024.
194 funds tracked by Wall St. Rank held Tarsus Pharmaceuticals as of Q1 2025.

Based on Prelude Capital Management's 13F filing for Q1 2025, filed 15 May 2025.